The maker of cancer drugs and high-tech chemicals for flat panel displays has said it plans to cut costs by an as yet unspecified amount through 2018 with a first phase running until end-2013 after a number of setbacks in its drug development pipeline.
"We do not plan to make any major acquisitions during this first phase of the programme. However, we will continue to strengthen our business through in-licensing or targeted acquisitions if the opportunities arise," CEO Karl-Ludwig Kley said, according to a prepared speech for Merck's annual shareholder meeting.
Overall cost cuts would be significant but the company would seek to cut jobs in Germany on a voluntary basis as far as possible, he added. (Ver)
Y en España:
Merck anuncia un ERE para reducir un 20% su plantilla española
Entradas
3 comentarios:
Perdon, pero estais hablando en los dos articulos de las dos Merck. La primera noticia se refiere a la compañía Americana, conocida en el mundo por las siglas MSD y la segunda noticia se refiere a Merck KGaA (La Alemana)
Fernando, hay un error en tu texto, las noticias que adjuntais son no son de la misma compañía. La primera se refiere a Merck Americana, universalmente conocida como MSD. La segunda noticia se refiere a Merck KGaA, la Alemana. Aun asi no deja de ser igualmente triste un nuevo anuncio de ERE en el sector... me pregunto donde va a llegar esto...
Un saludo
Muchas gracias anónimos...
Corregido el "horror". Errare humanum est.
Publicar un comentario